To begin to test the effect of trastuzumab-based therapies on Irf6 in human breast tumors, we used a pilot cohort of 11 patients with locally advanced breast cancers treated at the QEII Health Centre, Halifax, NS, Canada, with neoadjuvant trastuzumab and chemotherapy prior to surgical tumor resection. This evidence concerns the gene IRF6 and breast neoplasm.